Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in HSCT-TMA
NCT04543591Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of ravulizumab in thrombotic microangiopathy (TMA), sponsored by Alexion Pharmaceuticals. Started Dec 2020; status: completed.
02
Drugs
ravulizumab
03
Conditions
thrombotic microangiopathy (TMA)
Beyond the preview
Go deeper on NCT04543591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543591.